Analysts Set Haemonetics Co. (NYSE:HAE) PT at $108.78

Shares of Haemonetics Co. (NYSE:HAE - Get Free Report) have been given an average rating of "Moderate Buy" by the nine ratings firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $108.78.

HAE has been the subject of a number of recent analyst reports. Barrington Research restated an "outperform" rating and set a $108.00 price target on shares of Haemonetics in a research report on Wednesday, December 4th. CL King initiated coverage on Haemonetics in a research report on Friday, September 13th. They set a "buy" rating and a $116.00 target price for the company. Raymond James upgraded Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 target price on the stock in a research note on Friday, November 8th. BTIG Research initiated coverage on Haemonetics in a report on Tuesday, September 10th. They set a "buy" rating and a $112.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $112.00 target price on shares of Haemonetics in a research note on Tuesday, December 3rd.

Haemonetics Stock Performance

Shares of Haemonetics stock traded down $1.46 during trading hours on Friday, reaching $75.44. The company had a trading volume of 1,502,820 shares, compared to its average volume of 555,120. The firm has a market cap of $3.79 billion, a PE ratio of 31.30, a price-to-earnings-growth ratio of 1.29 and a beta of 0.38. Haemonetics has a one year low of $70.25 and a one year high of $97.97. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09. The business has a fifty day simple moving average of $81.38 and a 200 day simple moving average of $81.30.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping the consensus estimate of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The business had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. During the same quarter last year, the company earned $0.99 EPS. The firm's revenue was up 8.6% compared to the same quarter last year. On average, analysts anticipate that Haemonetics will post 4.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Commonwealth Equity Services LLC increased its stake in shares of Haemonetics by 3.3% in the second quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier's stock worth $304,000 after buying an additional 117 shares during the period. Vontobel Holding Ltd. increased its position in shares of Haemonetics by 3.8% in the third quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier's stock valued at $392,000 after acquiring an additional 180 shares during the period. Arizona State Retirement System raised its stake in shares of Haemonetics by 2.0% during the second quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier's stock valued at $1,176,000 after acquiring an additional 272 shares during the last quarter. Keene & Associates Inc. raised its stake in shares of Haemonetics by 3.0% during the third quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier's stock valued at $818,000 after acquiring an additional 298 shares during the last quarter. Finally, Versor Investments LP boosted its holdings in shares of Haemonetics by 9.1% during the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier's stock worth $289,000 after purchasing an additional 300 shares during the period. 99.67% of the stock is owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.